Specimen materials, target values and commutability for external quality assessment (proficiency testing) schemes

被引:83
作者
Miller, WG [1 ]
机构
[1] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA
关键词
external quality assessment; proficiency testing; reference materials; commutability; matrix interference; matrix bias;
D O I
10.1016/S0009-8981(02)00370-4
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The objective of external quality assessment is to evaluate clinical acceptability of laboratory results. It is desirable to evaluate intermethod harmonization and traceability to a reference system. Methods: Conventional matrix-modified processed materials are used in most programs, because they can be produced in large quantities, can have multiple abnormal analytes in the same vial and have excellent stability. The principal limitation of these materials is non-commutability which makes them unsuitable for traceability or harmonization evaluation. Peer group evaluation is used which allows an individual laboratory to confirm appropriate use of a measurement technology and a manufacturer to monitor uniformity in their calibration transfer process. Authentic clinical specimen pools provide commutability but are limited by the quantity available and number of analytes at pathologic levels in the same vial. Hybrid approaches have used authentic clinical specimen pools in conjunction with non-commutable processed materials to determine method-specific matrix-corrected target values which have enabled evaluation of traceability to reference methods. Conclusions: Conventional processed materials are limited by non-commutability. Pooled clinical specimens are limited by availability. When used together, external quality assessment can evaluate traceability to reference systems and harmonization between test procedures. (C) 2002 Elsevier Science B.V All rights reserved.
引用
收藏
页码:25 / 37
页数:13
相关论文
共 44 条
  • [1] [Anonymous], 1999, C37A NCCLS
  • [2] BAADENHUIJSEN H, 1995, CLIN CHEM, V41, P724
  • [3] A model for harmonization of routine clinical chemistry results between clinical laboratories
    Baadenhuijsen, H
    Scholten, R
    Willems, HL
    Weykamp, CW
    Jansen, RTP
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2000, 37 : 330 - 337
  • [4] Baadenhuijsen H, 2002, CLIN CHEM, V48, P1520
  • [5] BELK WP, 1947, AM J CLIN PATHOL, V17, P853
  • [6] Carobene A, 1997, CLIN CHEM, V43, P1342
  • [7] Cattozzo G, 2001, CLIN CHEM, V47, P2108
  • [8] Myoglobin and creatine kinase isoenzyme MB mass assays: intermethod behaviour of patient sera and commercially available control materials
    Cattozzo, G
    Franzini, C
    d'Eril, GVM
    [J]. CLINICA CHIMICA ACTA, 2001, 303 (1-2) : 55 - 60
  • [9] Cobbaert C, 2002, CLIN CHEM, V48, P1526
  • [10] Intermethod variation in serum carcinoembryonic antigen (CEA) measurement. Fresh serum pools and control materials compared
    Dominici, R
    Cabrini, E
    Cattozzo, G
    Ceriotti, F
    Grazioli, V
    Scapellato, L
    Franzini, C
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (02) : 167 - 173